Tagged with PR

Turkey After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to her country by improving patients’ access to life-saving therapies.   For Russ, what began as a consultant role at McKinsey…

Saudi Arabia As part of Saudi Arabia’s ambitious ‘Vision 2030’ economic transformation plan, the country has centralised the public procurement of medications through the National Unified Procurement Company for Medical Supplies (NUPCO). Here, some of the Kingdom’s most prominent pharma leaders weigh in on the impact of this new system for their…

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of the company from 30 to 300 employees. Here, he shares his insights on why M&A may be a better strategy…

Switzerland While once considered the land of milk and honey within Europe in terms of market access and reimbursement for innovative pharmaceuticals, Switzerland is increasingly tightening its belt on this front in line with its European neighbours. Indeed, this year two cost containment packages are under discussion in the Swiss parliament…

China Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.”   We want…

Global Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland outlines how AI has already begun to transform pharmaceutical strategy and highlights five ways in which it can be better utilised in pricing and market access decision making.   Artificial intelligence (AI) has been creating a buzz in…

China Genetron Health is a publicly-traded China-based precision oncology company, covering the “full-cycle” of cancer care, from early screening, diagnosis, and treatment recommendations to continuous monitoring care. CEO and Co-Founder Sizhen Wang explains how the company obtained US FDA Breakthrough Device Designation, analyzes the Chinese biotech sector, and highlights their objective…

Korea The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and Samsung Bioepis’ first steps into the Australian market.   ‘Now is best time to develop Korean blockbuster drug’ (Korea Biomedical…

Switzerland Antonella Santuccione Chadha*, Head of Stakeholder Engagement for Alzheimer’s disease at Biogen and co-founder and CEO of the Women’s Brain Project, dives into the non-profit organization’s role in rethinking the way we look at sex and gender as a gateway to precision medicine. She explains how artificial intelligence (AI) is…

Switzerland After an illustrious career in oncology R&D, contributing greatly to the development of cutting-edge cancer therapies at Novartis and Gilead, Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019. In a recent conversation with PharmaBoardroom, Riva explained why he took on this unique new opportunity at…

Japan Following on from our recent compilations of 2020 new drug approvals in the USA, China, and Switzerland, see below for the Japanese PMDA’s new drug approvals list for April-October 2020. Made with Visme Infographic Maker  

China HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T: advanced degrees in different scientific fields, including a master’s in microbial engineering and chemical engineering and a PhD in molecular biology and genetics, an academic career at top US institutions…